MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Fri May 31 00:00:00 GMT-05:00 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Wed May 15 00:00:00 GMT-05:00 2019
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Tue May 14 00:00:00 GMT-05:00 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Tue May 14 00:00:00 GMT-05:00 2019
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Wed May 08 00:00:00 GMT-05:00 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Mon Apr 29 00:00:00 GMT-05:00 2019
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Thu Apr 25 00:00:00 GMT-05:00 2019
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Tue Apr 09 00:00:00 GMT-05:00 2019
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)
Thu Apr 04 00:00:00 GMT-05:00 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
![](https://daiichisankyo.us/o/dsi-new-theme/images/icn-pdf.png)